• Policy
• “Elderly polypharmacy rate Korea 70% vs OECD countries 48%"
• by Lee, Jeong-Hwan Oct 6, 2021 06:06am

• Policy
• The patient died due to the delay in Kymriah benefits
• by Lee, Jeong-Hwan Oct 6, 2021 06:06am

• Policy
• Boryung's Dukarb Plus is about to be commercialized
• by Lee, Tak-Sun Oct 5, 2021 05:58am

• Policy
• Rate of reimbursement expansions is falling?
• by Lee, Hye-Kyung Oct 5, 2021 05:56am

• Policy
• Kymriah's fast track is needed
• by Kim, Jung-Ju Oct 5, 2021 05:56am

• Policy
• Botulinum toxin by fraudulent means can be revoked
• by Lee, Jeong-Hwan Oct 1, 2021 06:08am

• Policy
• Domestic new drugs shouldn't be discriminated against
• by Lee, Jeong-Hwan Oct 1, 2021 06:08am

• Policy
• Pts can participate in Phase III tx for terminal cancer
• by Lee, Tak-Sun Sep 30, 2021 05:57am

• Policy
• 24 new drugs receive ₩177.9 billion benefit this year
• by Kim, Jung-Ju Sep 30, 2021 05:56am

• Policy
• Will a treatment for resistant hypertension be released?
• by Lee, Tak-Sun Sep 29, 2021 05:54am